VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions
Greco, O., Joiner, M.C., Doleh , A. and Scott, S.D. (2005) VP22-mediated intercellular transport for suicide gene therapy under oxic and hypoxic conditions. Gene Therapy, 12 (12). pp. 974-979. ISSN 0969-7128 (print), 1476-5462 (electronic) (doi:10.1038/sj.gt.3302482)Full text not available from this repository.
During herpes simplex virus type 1 (HSV 1) infection, the tegument protein VP22 is exported from infected cells to the nuclei of surrounding uninfected cells. These intercellular transport characteristics have prompted the exploitation of VP22 fusion proteins for cancer gene therapy, with the goal of maximizing the bystander effect. Since solid tumors contain hypoxic cell populations that are often refractive to therapy, for efficient targeting, it would be optimal if VP22 functioned even at reduced oxygen concentrations. In the present work, VP22 activity under hypoxic conditions was examined for the first time. Plasmid-transfected human glioma U87-MG and U373-MG cells expressing VP22 fused to the green fluorescent protein (GFP) showed protein export to untransfected cells under tumor oxygenation conditions (0–5% O2). For suicide gene therapy, VP22 activity was demonstrated under hypoxia by coupling VP22 to the HSV thymidine kinase (HSVtk). In the presence of the prodrug ganciclovir, cell cultures expressing VP22-HSVtk showed a significant increase in toxicity compared with cells transfected with a construct containing HSVtk only, under all tested conditions. To allow effective suicide gene therapy and simultaneous visualization of therapeutic enzyme localization, a triple fusion protein GFP-HSVtk-VP22 was engineered. Functionality of all components was demonstrated under oxia and hypoxia.
|Additional Information:|| advance online publication, February 24, 2005  This article is now free to access, please see http://www.nature.com/authors/policies/license.html|
|Uncontrolled Keywords:||bystander effect, GFP, HSVtk, GCV, glioma, fusion proteins|
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)|
T Technology > TP Chemical technology
|School / Department / Research Groups:||Medway School of Pharmacy|
|Last Modified:||29 Jun 2012 11:08|
Actions (login required)